1. Home
  2. CAPT vs SNGX Comparison

CAPT vs SNGX Comparison

Compare CAPT & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAPT

Captivision Inc.

N/A

Current Price

$0.42

Market Cap

13.2M

Sector

Finance

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

N/A

Current Price

$1.22

Market Cap

12.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPT
SNGX
Founded
2005
1987
Country
South Korea
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
12.0M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
CAPT
SNGX
Price
$0.42
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
152.1K
107.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$1.02
52 Week High
$1.93
$6.23

Technical Indicators

Market Signals
Indicator
CAPT
SNGX
Relative Strength Index (RSI) 43.83 56.30
Support Level $0.40 $1.19
Resistance Level $0.46 $1.47
Average True Range (ATR) 0.02 0.06
MACD 0.00 0.02
Stochastic Oscillator 43.40 75.34

Price Performance

Historical Comparison
CAPT
SNGX

About CAPT Captivision Inc.

Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: